NDA 017532 · Sanofi Aventis US
Diabeta
Glyburide · Oral · Sulfonylurea
Last checked: Nov 20, 2026Latest source record: Jan 11, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1984
May 1, 1984
Approved uses
1
Original approval plus efficacy supplements
Registered trials
119
30 Phase 3, 2 recruiting
FAERS reports
24,129
15,175 serious, 2,143 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 1, 2021.
INDICATIONS AND USAGE Glyburide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 1, 1984 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
- DIABETA · GLYBURIDE 2.5MG · TABLET, ORAL · Prescription · TE AB2
- DIABETA · GLYBURIDE 5MG · TABLET, ORAL · Prescription · TE AB2
- DIABETA · GLYBURIDE 1.25MG · TABLET, ORAL · Prescription · TE AB2
Clinical trials
Interventional ClinicalTrials.gov studies with "Glyburide" as an intervention, any sponsor and status, largest first.
- RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in DiabetesPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00379769 · 4,447 participants · Start Apr 2001 · Primary completion Dec 2008
Drug: Rosiglitazone; Sulfonylurea and 1 more · For: Diabetes Mellitus, Type 2
Sites: Miranda, Australia; Randwick, Australia; Wollongong, Australia · 446 sites in all
- Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/GlibenclamidePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00279045 · 4,426 participants · Start Jan 3, 2000 · Primary completion Jun 1, 2006
Drug: Rosiglitazone; glyburide and 1 more · For: Diabetes Mellitus, Type 2
Sites: Anniston, Alabama; Birmingham, Alabama; Mesa, Arizona · 490 sites in all
- Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention TrialPivotal-lookingStatus unknown
Italian Society of DiabetologyAcademic, hospital or other
NCT00700856 · 3,371 participants (planned) · Start Sep 2008 · Primary completion Dec 2018
Drug: add-on pioglitazone; add-on sulphonylurea · For: Type 2 Diabetes Mellitus; Cardiovascular Disease
Sites: Seriate, Italy; Treviglio, Italy; Lanciano, Italy · 61 sites in all
- Safety Study of Pioglitazone Compared To Glyburide on Liver FunctionPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00494312 · 2,120 participants · Start Oct 2000 · Primary completion Jun 2005
Drug: Pioglitazone; Glyburide · For: Diabetes Mellitus; Liver
- Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01131182 · 1,147 participants · Start Jun 13, 2010 · Primary completion Nov 4, 2010
Drug: Sitagliptin phosphate; Comparator: Sulfonylurea and 1 more · For: Type 2 Diabetes Mellitus (T2DM)
- Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational DiabetesPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01731431 · 914 participants · Start May 18, 2012 · Primary completion Mar 15, 2017
Drug: Glyburide · For: Diabetes; Gestational
Sites: Paris, France
- Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01340768 · 870 participants · Start Jun 22, 2010 · Primary completion Sep 21, 2011
Drug: Sitagliptin; Sulfonylurea and 1 more · For: Type 2 Diabetes Mellitus
- A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With SulfonylureasPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00313313 · 768 participants · Start Apr 2006 · Primary completion Sep 2007
Drug: Saxagliptin; Saxagliptin and 4 more · For: Diabetes
Sites: Jonesboro, Arkansas; Searcy, Arkansas; Alhambra, California · 115 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased3,044
- nausea2,043
- weight decreased1,546
- drug ineffective1,431
- diarrhoea1,311
- dizziness1,220
- hypoglycaemia1,210
- blood glucose decreased1,167
- fatigue1,158
- dyspnoea1,099
- asthenia1,052
- vomiting1,046
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,141 |
| 2005 | 1,216 |
| 2006 | 1,948 |
| 2007 | 1,899 |
| 2008 | 1,503 |
| 2009 | 1,225 |
| 2010 | 1,477 |
| 2011 | 1,813 |
| 2012 | 1,497 |
| 2013 | 1,199 |
| 2014 | 1,133 |
| 2015 | 1,454 |
| 2016 | 1,172 |
| 2017 | 891 |
| 2018 | 905 |
| 2019 | 812 |
| 2020 | 686 |
| 2021 | 528 |
| 2022 | 432 |
| 2023 | 426 |
| 2024 | 303 |
| 2025 | 267 |
| 2026 | 201 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Aug 10, 2026
Diabeta, Tablet, 5 mg (NDC 0093-9364-01). A business decision was made to discontinue manufacture of the drug.
To Be Discontinued · updated Aug 10, 2026
Diabeta, Tablet, 1.25 mg (NDC 0093-9477-53). A business decision was made to discontinue manufacture of the drug.
To Be Discontinued · updated Aug 10, 2026
Diabeta, Tablet, 2.5 mg (NDC 0093-9433-01). A business decision was made to discontinue manufacture of the drug.
To Be Discontinued · updated Aug 10, 2026
Diabeta, Tablet, 5 mg (NDC 0093-9364-10). A business decision was made to discontinue manufacture of the drug.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral Glucose-Lowering Agents vs Insulin for Gestational Diabetes: A Randomized Clinical Trial.
Rademaker D, de Wit L, Duijnhoven RG, et al. · JAMA 2025 · Comparative Study, Equivalence Trial
- Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical Trial.
Martin P, Tamblyn R, Benedetti A, et al. · JAMA 2018 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- [Management of gestational diabetes].
Jacqueminet S, Jannot-Lamotte MF · J Gynecol Obstet Biol Reprod (Paris) 2010 · Systematic Review
- Effects of Pregnancy on the Pharmacokinetics of Metformin.
Liao MZ, Flood Nichols SK, Ahmed M, et al. · Drug Metab Dispos 2020 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Comparative impact of pharmacological treatments for gestational diabetes on neonatal anthropometry independent of maternal glycaemic control: A systematic review and meta-analysis.
Tarry-Adkins JL, Aiken CE, Ozanne SE · PLoS Med 2020 · Comparative Study, Meta-Analysis
- Can glyburide be advocated over subcutaneous insulin for perinatal outcomes of women with gestational diabetes? A systematic review and meta-analysis.
Helal KF, Badr MS, Rafeek ME, et al. · Arch Gynecol Obstet 2020 · Meta-Analysis, Systematic Review
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.